Security Snapshot

RECURSION PHARMACEUTICALS, INC. - Class A Common Stock (RXRX) Institutional Ownership

CUSIP: 75629V104

13F Institutional Holders and Ownership History from Q1 2019 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

330

Shares (Excl. Options)

324,242,816

Price

$4.09

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Class A Common Stock
Symbol
RXRX on Nasdaq
Shares outstanding
514,715,255
Price per share
$3.07
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
324,242,816
Total reported value
$1,326,214,681
% of total 13F portfolios
0%
Share change
+12,336,221
Value change
+$25,224,512
Number of holders
330
Price from insider filings
$3.07
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • RXRX - RECURSION PHARMACEUTICALS, INC. - Class A Common Stock is tracked under CUSIP 75629V104.
  • 330 institutions reported positions in Q4 2025.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 330 to 19 between Q4 2025 and Q1 2026.
  • Reported value moved from $1,326,214,681 to $1,677,880.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 330 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 75629V104?
CUSIP 75629V104 identifies RXRX - RECURSION PHARMACEUTICALS, INC. - Class A Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock (RXRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARK Investment Management LLC 7.2% -15% $152,625,941 +$20,329,177 37,316,856 +15% ARK Investment Management LLC 31 Dec 2025
BAILLIE GIFFORD & CO 4.6% $97,239,635 23,774,972 BAILLIE GIFFORD & CO 31 Dec 2025
BlackRock, Inc. 6.1% $134,057,558 23,436,636 BlackRock, Inc. 31 Dec 2024
RA CAPITAL MANAGEMENT, L.P. 2% $44,187,549 7,725,096 RA Capital Management, L.P. 31 Dec 2024
Kim Yohan 5.9% $1,530,100 267,500 Yohan Kim 04 Apr 2025

As of 31 Dec 2025, 330 institutional investors reported holding 324,242,816 shares of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock (RXRX). This represents 63% of the company’s total 514,715,255 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock (RXRX) together control 54% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 9.2% 47,187,759 +19% 0% $192,997,934
BlackRock, Inc. 7.6% 38,866,779 +22% 0% $158,965,127
ARK Investment Management LLC 7.3% 37,316,856 +11% 1% $152,625,940
STATE STREET CORP 4.9% 25,333,888 +39% 0% $103,615,602
BAILLIE GIFFORD & CO 4.6% 23,774,972 -0.85% 0.08% $97,239,635
SOFTBANK GROUP CORP. 2.6% 13,636,515 -7% 0.36% $55,773,346
GEODE CAPITAL MANAGEMENT, LLC 2.1% 10,934,252 +14% 0% $44,731,450
MIC Capital Management UK LLP 1.9% 9,644,032 0% 8.9% $39,444,095
Amova Asset Management Americas, Inc. 1.2% 6,221,025 -17% 0.29% $25,381,782
Sumitomo Mitsui Trust Group, Inc. 1.2% 6,221,025 -17% 0.01% $25,443,992
Data Collective IV GP, LLC 1.2% 5,941,120 0% 42% $24,299,181
NORGES BANK 1.1% 5,739,064 0% $23,472,772
MORGAN STANLEY 1.1% 5,657,577 -22% 0% $23,139,494
Lingotto Investment Management LLP 0.96% 4,931,057 +34% 0.36% $20,168,023
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.85% 4,396,104 -18% 0.02% $17,980,065
CITADEL ADVISORS LLC 0.82% 4,229,999 +214% 0.01% $17,300,696
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 0.79% 4,075,219 -2.9% 0% $16,667,644
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.78% 3,994,651 +16% 0% $16,338,123
DCVC Opportunity Fund II GP, LLC 0.77% 3,951,141 0% 97% $16,160,167
UBS Group AG 0.72% 3,692,022 -1.6% 0% $15,100,371
NORTHERN TRUST CORP 0.67% 3,439,949 +3.1% 0% $14,069,391
FMR LLC 0.63% 3,241,892 +0.4% 0% $13,259,340
TWO SIGMA INVESTMENTS, LP 0.6% 3,075,123 +25% 0.02% $12,577,253
IQ EQ FUND MANAGEMENT (IRELAND) Ltd 0.47% 2,404,118 +35% 0.68% $9,832,843
FIRST TRUST ADVISORS LP 0.44% 2,266,691 +26% 0.01% $9,270,766

Institutional Holders of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock (RXRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 537,770 $1,677,880 +$1,896 $3.07 19
2025 Q4 324,242,816 $1,326,214,681 +$25,224,512 $4.09 330
2025 Q3 324,190,091 $1,581,950,465 +$66,787,219 $4.88 321
2025 Q2 310,182,949 $1,569,493,304 +$26,510,398 $5.06 329
2025 Q1 304,244,163 $1,609,644,830 -$29,277,099 $5.29 330
2024 Q4 304,544,141 $2,058,776,356 +$268,240,445 $6.76 310
2024 Q3 264,392,743 $1,743,289,324 +$54,064,157 $6.59 262
2024 Q2 251,836,128 $1,888,574,788 +$298,622,706 $7.50 264
2024 Q1 212,714,397 $2,120,552,518 +$62,304,334 $9.97 242
2023 Q4 206,501,532 $2,035,976,922 +$306,507,294 $9.86 194
2023 Q3 152,228,034 $1,164,429,792 +$189,175,887 $7.65 189
2023 Q2 127,547,789 $952,749,699 +$12,757,431 $7.47 155
2023 Q1 126,153,704 $841,388,403 +$14,595,249 $6.67 157
2022 Q4 123,786,379 $954,397,559 +$134,707,594 $7.71 144
2022 Q3 113,749,582 $1,210,251,991 +$75,709,491 $10.64 141
2022 Q2 106,463,853 $861,094,172 +$96,496,440 $8.14 130
2022 Q1 95,043,699 $680,250,380 -$12,978,444 $7.16 124
2021 Q4 94,346,907 $1,616,473,942 +$295,962,917 $17.13 122
2021 Q3 54,909,739 $1,262,978,377 +$181,552,159 $23.01 82
2021 Q2 46,974,230 $1,714,334,294 +$1,714,333,294 $36.50 75
2021 Q1 30 $1,000 $33.33 1
2020 Q4 30 $1,000 $33.33 1
2020 Q3 30 $1,000 $33.33 1
2020 Q2 30 $1,000 $33.33 1
2020 Q1 30 $1,000 $33.33 1
2019 Q4 30 $1,000 $33.33 1
2019 Q3 30 $1,000 $33.33 1
2019 Q2 30 $1,000 $33.33 1
2019 Q1 30 $1,000 $33.33 1

Sponsored